PXD061023

PXD061023 is an original dataset announced via ProteomeXchange.

Title	Preclinical Evaluation of seco-Duocarmycin SA in Aggressive Glioblastoma Cell Lines
Description	Glioblastoma multiforme (GBM) is among the most lethal primary brain tumors and is characterized by significant cellular heterogeneity and resistance to conventional therapies. This study investigates the efficacy of seco-duocarmycin SA (seco-DSA), a novel DNA alkylating agent. Initial investiga-tions using colony formation assay revealed that seco-DSA exhibits remarkable potential with IC50 values lower than it’s natural DSA counterpart. Cell viability assay indicated that LN18 cells showed a markedly greater sensitivity to DSA than T98G cells. Furthermore, seco-DSA achieved its full cytotoxic effect within 8 h of drug incubation in GBM cell lines. Although seco-DSA induced a concentration-dependent increase in apoptotic cell death, the extent of apoptosis did not fully ac-count for the observed decrease in cell viability. Instead, seco-DSA treatment resulted in significant cell cycle arrest in S and G2/M phases. These findings suggest that seco-DSA’s cytotoxicity in GBM cells is primarily due to its ability to disrupt cell cycle progression, though the precise mechanisms of actions remain to be fully established, and further research is needed. Proteomic analysis of treated cells also indicates dysregulation of proteins involved in senescence, apoptosis, and DNA repair, alluding to seco-DSA induced arrest as a major mechanism of GBM disruption. Our reports promote the future exploration of seco-DSA’s therapeutic potential, representing a critical step toward de-veloping a more targeted and effective treatment for GBM.
HostingRepository	PRIDE
AnnounceDate	2025-05-07
AnnouncementXML	Submission_2025-05-07_07:27:13.905.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Quanqing Zhang
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	No PTMs are included in the dataset
Instrument	Orbitrap Fusion

Revision	Datetime	Status	ChangeLog Entry
0	2025-02-20 16:35:02	ID requested
⏵ 1	2025-05-07 07:27:14	announced

10.3390/ijms26062766;

Morcos A, Jung Y, Fuller RN, Bertucci A, Nguyen A, Zhang Q, Emge T, Boyle KE, Wall NR, Vazquez M, Seco-Duocarmycin SA in Aggressive Glioblastoma Cell Lines. Int J Mol Sci, 26(6):(2025) [pubmed]

submitter keyword: proof of concept,glioblastoma multiforme, resistance, cellular mechanisms, seco-DSA, duocarmycin, potency

Marcelo Vazquez
contact affiliation	Department of Radiation Medicine, James M. Slater, MD Proton Treatment & Research Center, Loma Linda University Health, Loma Linda, CA 92350, USA
contact email	marcelo.vazquez@cnl.ca
lab head
Quanqing Zhang
contact affiliation	University of California Riverside
contact email	zqq84490411@gmail.com
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2025/05/PXD061023

PRIDE project URI

• PRIDE
  1. PXD061023
     1. Label: PRIDE project
     2. Name: Preclinical Evaluation of seco-Duocarmycin SA in Aggressive Glioblastoma Cell Lines